Ülke: Malezya
Dil: İngilizce
Kaynak: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
LOSARTAN POTASSIUM
MERCK SHARP & DOHME (MALAYSIA) SDN BHD
LOSARTAN POTASSIUM
30Tablet Tablets; 10 Tablet Tablets
MERCK SHARP & DOHME LTD
LOCAL PRODUCT CIRCULAR LPC -MK0954 -T-032018 -Malaysia Tablets COZAAR (losartan potassium) I. THERAPEUTIC CLASS COZAAR (losartan potassium), the first of a new class of agents for the treatment of hypertension, is an angiotensin II receptor (type AT 1) antagonist. COZAAR also provides a reduction in the combined risk of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy and provides renal protection for type 2 diabetic patients with proteinuria. II. CLINICAL PHARMACOLOGY Mechanism of Action Angiotensin II, a potent vasoconstrictor, is the primary active hormone of the renin- angiotensin system, and a major determinant of the pa thophysiology of hypertension. Angiotensin II binds to the AT 1 receptor found in many tissues (e.g., vascular smooth muscle, adrenal gland, kidneys, and the heart) and elicits several important biological actions, including vasoconstriction and the release of aldosterone. Angiotensin II also stimulates sm ooth muscle cell proliferation. A second angiotensin II receptor has been identified as the AT 2 receptor subtype, but it plays no known role in cardiovascular homeostasis. Losartan is a potent, syn thetic, orally active compound. Based on binding and pharmacological bioassays, it binds selectively to the AT 1 receptor. In vitro and in vivo , both losartan and its pharmacologically active carboxylic acid metabolite (E -3174) block all physiologically relevant actions of angiotensin II, regardless of the source or route of synthesis. In contrast to some peptide antagonists of angiotensin II, losartan has no agonist effects. 1 Belgenin tamamını okuyun